The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In general, all nontopical NSAIDs in doses adequate to reduce inflammation and pain can affect BP levels in both normotensive and hypertensive individuals.182”
From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [182]
Citations
Cites
Vane, J. R., Bakhle, Y. S., & Botting, R. M. (1998) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.97 · Cited by 2,763
Warner, T. D., Giuliano, F., Vojnovic, I., Bukasa, A., Mitchell, J. A., & Vane, J. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.13.7563 · Cited by 1,521
Self-citationKearney, P. M., Baigent, C., Godwin, J., Halls, H. J., Emberson, J., & Patrono, C. (2006) · BMJ · doi:10.1136/bmj.332.7553.1302 · Cited by 1,440
Großer, T. (2005) · Journal of Clinical Investigation · doi:10.1172/jci27291 · Cited by 1,031
Topper, J., Cai, J., Falb, D., & Gimbrone, M. (1996) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.93.19.10417 · Cited by 922
Graham, D. J., Campen, D. H., Hui, R. L., Spence, M. M., Cheetham, C., Levy, G. D., Shoor, S., & Ray, W. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17864-7 · Cited by 913
Henry, D. A., Lim, L. L.-Y., Rodriguez, L. A. G., Perez‐Gutthann, S., Carson, J. L., Griffin, M. R., Savage, R. L., Logan, R., Moride, Y., Hawkey, C. J., et al. (1996) · BMJ · doi:10.1136/bmj.312.7046.1563 · Cited by 827
Antman, E. M., Bennett, J. S., Daugherty, A., Furberg, C., Roberts, H., & Taubert, K. A. (2007) · Circulation · doi:10.1161/circulationaha.106.181424 · Cited by 804
Farkouh, M. E., Kirshner, H. S., Harrington, R. A., Ruland, S. D., Verheugt, F. W. A., Schnitzer, T. J., Burmester, G. R., Mysler, E., Hochberg, M. C., Doherty, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16894-3 · Cited by 490
Effects of Nonsteroidal Antiinflammatory Drugs on Platelet Function and Systemic Hemostasis
Schafer, A. I. (1995) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1995.tb04050.x · Cited by 370
Hecken, A. V., Schwartz, J. I., Depré, M., Lepeleire, I. D., Dallob, A. L., Tanaka, W. K., Wynants, K., Buntinx, A., Arnout, J., Wong, P. H., et al. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/009127000004001005 · Cited by 355
Mitchell, J. A., & Warner, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1929 · Cited by 276
Self-citationEffect on platelet aggregation of oral administration of 10 non‐steroidal analgesics to humans
Cronberg, S., Wallmark, E., & Söderberg, I. (1984) · Scandinavian Journal of Haematology · doi:10.1111/j.1600-0609.1984.tb02390.x · Cited by 147
Cardiovascular Effects of the Cyclooxygenase Inhibitors
White, W. B. (2007) · Hypertension · doi:10.1161/01.hyp.0000258106.74139.25 · Cited by 128
Farkouh, M. E., Greenberg, J., Jeger, R. V., Ramanathan, K., Verheugt, F. W. A., Chesebro, J. H., Kirshner, H. S., Hochman, J. S., Lay, C. L., Ruland, S. D., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.066001 · Cited by 119
Balancing prostanoid activity in the human vascular system
Flavahan, N. A. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.01.003 · Cited by 104
Minimising the Adverse Effects of Ketorolac
Reinhart, D. J. (2000) · Drug Safety · doi:10.2165/00002018-200022060-00007 · Cited by 104
Niemi, T., Taxell, C., & Rosenberg, P. H. (1997) · Acta Anaesthesiologica Scandinavica · doi:10.1111/j.1399-6576.1997.tb04657.x · Cited by 93
Mitchell, J. A., Lucas-Domínguez, R., Vojnovic, I., Hasan, K., Pepper, J., & Warner, T. D. (2006) · The FASEB Journal · doi:10.1096/fj.06-6615com · Cited by 73
Self-citationThe pharmacology of selective inhibition of COX-2
Großer, T. (2006) · Thrombosis and Haemostasis · doi:10.1160/th06-08-0444 · Cited by 60
Nomenclature for COX-2 Inhibitors
Vane, J. R., & Warner, T. D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02837-3 · Cited by 50
Self-citationNSAIDs, Coxibs, and the Intestine
Hawkey, C. J. (2006) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200605001-00013 · Cited by 34
Cited by
Sorted by citations
Carey, R. M., Calhoun, D. A., Bakris, G. L., Brook, R. D., Daugherty, S. L., Dennison-Himmelfarb, C. R., Egan, B. M., Flack, J. M., Gidding, S. S., Judd, E., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000084 · Cited by 1,153
“In general, all nontopical NSAIDs in doses adequate to reduce inflammation and pain can affect BP levels in both normotensive and hypertensive individuals.(182) The results of meta-analyses have indicated that the average increase in mean arterial pressure is highly variable, with a range of reports from 2 to 5 mm Hg.”
BackgroundDiagnosis and Management of Lumbar Spinal Stenosis: A Review
Katz, J. N., Zimmerman, Z. E., Mass, H., & Makhni, M. C. (2022) · JAMA · doi:10.1001/jama.2022.5921 · Cited by 562
Conaghan, P. G. (2011) · Rheumatology International · doi:10.1007/s00296-011-2263-6 · Cited by 420
“Based on clinical evidence and an increased understanding of differences between individual NSAIDs, an alternative concept has been proposed that incorporates the association between increasing dose and NSAID-associated gastrointestinal and cardiovascular risk [77].”
BackgroundNonsteroidal Anti-Inflammatory Drugs and the Kidney
Hörl, W. H. (2010) · Pharmaceuticals · doi:10.3390/ph3072291 · Cited by 298
“In addition, inhibition PG synthesis may cause hypertension, but COX-2 selectivity alone does not define the cardiovascular risk associated with NSAIDs [149].”
BackgroundThe use of lipid-based nanocarriers for targeted pain therapies
Hua, S., & Wu, S. Y. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00143 · Cited by 268
“However, they are associated with numerous interactions with other medications and have serious side effects to the gastrointestinal tract, kidneys, and cardiovascular system (Rittner et al., 2005; Warner and Mitchell, 2008).”
Background
Metadata
- Authors
- Warner, T. D., & Mitchell, J. A.
- Affiliations
- Queen Mary University of London (GB)
- Royal Brompton Hospital (GB)
- Corresponding author
- Warner, Timothy D
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2008-01
- Volume
- 371
- Issue
- 9608
- Pages
- 270-273
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2164162242
- Cited by
- 166
- References
- 22
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 5 · 2023: 3 · 2022: 7 · 2021: 8 · 2020: 8 · 2019: 4 · 2018: 10 · 2017: 8 · 2016: 8 · 2015: 7 · 2014: 12 · 2013: 9 · 2012: 16
- FWCI
- 13.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
- Keywords
- COX-2 selectivity, nonsteroidal anti-inflammatory drugs, cardiovascular risk, thrombosis risk, gastrointestinal risk, cyclooxygenase inhibition, cyclooxygenase-1, cyclooxygenase-2, etoricoxib, rofecoxib, celecoxib, lumiracoxib, drug safety, cardiovascular adverse events, gastrointestinal adverse effects, American Heart Association guidelines
- MeSH terms
- Anti-Inflammatory Agents, Non-Steroidal, Dose-Response Relationship, Drug, Gastrointestinal Diseases, Humans, Myocardial Infarction, Risk Factors, Thrombosis, Cyclooxygenase 2 Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
